|
|||||
|
|
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms |
|
| Authors: | S. Caponi E. Vasile N. Funel N. De Lio D. Campani L. Ginocchi M. Lucchesi C. Caparello M. Lencioni C. Cappelli F. Costa L. Pollina S. Ricci F. Mosca A. Falcone U. Boggi |
| Affiliation: | 1. Department of Oncology, Transplants, and New Technologies, U.O. Oncologia 2 Universitaria, Division of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Polo Oncologico Area Vasta Nord-Ovest, Istituto Toscano Tumori, Via Roma 67, 56126 Pisa, Italy;2. Department of Oncology, Transplants, and New Technologies in Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy;3. Department of Surgery, Division of Pathology, University of Pisa, Via Roma 55, 56126 Pisa, Italy;4. Department of Oncology, Transplants, and New Technologies, Division of General Surgery and Transplants, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy;5. Department of Diagnostic, Vascular and Interventional Radiology and Nuclear Medicine, Division of Diagnostic and Interventional Radiology, Azienda Ospedaliero-Universitaria Pisana, Via Paradisa 2, 56100 Pisa, Italy;6. Department of Laboratory Medicine, Division of Pathology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy |
| Abstract: | AimsThe incidence of intraductal papillary mucinous neoplasm (IPMN) is rising and these neoplasms now represent up to 25% of resected pancreatic neoplasms. The optimal postoperative management of resected invasive IPMN is still debated in the absence of large prospective clinical trials and of validated prognostic factors in this setting. The objective of our study was to identify potential prognostic factors and to investigate the role of adjuvant therapies for patients radically resected for invasive IPMN.MethodsWe retrospectively reviewed clinical and pathological data regarding a large series of patients with invasive IPMN who underwent surgical resection in the last six years at University Hospital of Pisa.ResultsSixty-four patients were considered for the analysis, thirty-three of whom received adjuvant chemotherapy with gemcitabine. In our series node involvement and high tumoral grade emerged as the major pathologic prognostic factors. Patients treated with adjuvant chemotherapy with gemcitabine experienced a longer disease-free survival than those who received surgery alone.ConclusionsGemcitabine-based chemotherapy seems beneficial as adjuvant treatment for patients with resected invasive IPMN. |
| Keywords: | Adjuvant chemotherapy Intraductal papillary mucinous neoplasms Pancreatic cancer Gemcitabine Prognostic factors |
| 本文献已被 ScienceDirect 等数据库收录！ | |